BioPharma Dive

Recent stories from BioPharma Dive.

BioPharma Dive Delilah Alvarado

Sanofi gains FDA clearance for Gaucher disease pill

The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.

Read at BioPharma Dive

BioPharma Dive Jonathan Gardner

China could ‘corner’ biopharmaceutical sector with new plan, US panel warns

A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”

Read at BioPharma Dive

BioPharma Dive Ben Fidler

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.

Read at BioPharma Dive

BioPharma Dive Rebecca Pifer Parduhn

‘Selling and marketing snake oil’: The debate over compounded GLP-1s

Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH conference.

Read at BioPharma Dive

BioPharma Dive Jonathan Gardner

White House pulls nomination for FDA nominee Overton

The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.

Read at BioPharma Dive

BioPharma Dive Kristin Jensen

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.

Read at BioPharma Dive

BioPharma Dive BioPharma Dive staff

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.

Read at BioPharma Dive

BioPharma Dive Delilah Alvarado

Roche breast cancer pill cleared by FDA

Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.

Read at BioPharma Dive

BioPharma Dive Kristin Jensen

AI drugmaker Isomorphic restocks with $5B fundraise

Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.

Read at BioPharma Dive

BioPharma Dive Gwendolyn Wu

Marrow sets out to challenge genetic medicines for severe blood diseases

Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.

Read at BioPharma Dive

BioPharma Dive Jonathan Gardner

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.

Read at BioPharma Dive

BioPharma Dive Ben Fidler

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.

Read at BioPharma Dive

BioPharma Dive Delilah Alvarado

J&J bets $2.2B on Ollin’s vision loss drug

The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

Read at BioPharma Dive

BioPharma Dive Ben Fidler

Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.

Read at BioPharma Dive

BioPharma Dive

The infrastructure decisions that will enable tomorrow’s biggest breakthroughs

Faster drug discovery depends on more than the model. What drug developers need to know about AI.

Read at BioPharma Dive

BioPharma Dive Kayt Leonard, Global Director, SAS

Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment

As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.

Read at BioPharma Dive

BioPharma Dive

Completing the circle: the next evolution in sustainable pharmaceutical blister packaging

Discover how innovative PET and PP lidding are advancing sustainable pharmaceutical blister packaging.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

Big-name investors pour $100M into DNA therapeutics developer Seawolf

The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.

Read at BioPharma Dive

BioPharma Dive Gwendolyn Wu

One of Europe’s leading VCs banks a €725M ‘crossover’ fund

Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

Read at BioPharma Dive

BioPharma Dive BioPharma Dive staff

Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties

Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

This week in charts: Brain drugs are back on venture’s minds

Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.

Read at BioPharma Dive

BioPharma Dive Gwendolyn Wu

Windward prices $175M IPO to advance China-licensed lung drugs

The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.

Read at BioPharma Dive

BioPharma Dive Jonathan Gardner

Blackstone bets $1.5B on Pfizer’s obesity drug

The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.

Read at BioPharma Dive

BioPharma Dive Kristin Jensen

Bristol Myers research chief to depart in ‘evolution’ of company’s structure

Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.

Read at BioPharma Dive

BioPharma Dive Kelly Bilodeau

The FDA has over 1k open jobs — and the staffing shortage is hitting pharma

The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.

Read at BioPharma Dive

BioPharma Dive Kristin Jensen

Drug price hikes in Germany could push US costs higher, study says

The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.

Read at BioPharma Dive

BioPharma Dive BioPharma Dive staff

AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

Read at BioPharma Dive

BioPharma Dive Delilah Alvarado

PepGen soars on promising early data for muscular dystrophy drug

While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.

Read at BioPharma Dive

BioPharma Dive Jonathan Gardner

Beam’s base editing therapy for sickle cell hits goal in pivotal trial

The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

Read at BioPharma Dive

BioPharma Dive Gwendolyn Wu

London biotech Oyster harvests $60M for tau-targeting brain drugs

Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

Read at BioPharma Dive

Older stories